Evaluation of the In Vitro Anti-Inflammatory Potential of Myxopyrum Smilacifolium Against Lipopolysaccharide-Induced Inflammation in HT-29 Intestinal Epithelial Cells

Author

Arathy Sreenivasan, Dr. Shan P Mohammed, Dr. Jyoti Harindran, Deepthi Krishna M, Sanusha T V, Sayoojys R, Shruthy P

Abstract

 Inflammation is a key pathophysiological mechanism underlying various mucosal and systemic disorders. This study investigated the in vitro anti-inflammatory efficacy of a Myxopyrum smilacifolium sample against lipopolysaccharide (LPS)-stimulated human colorectal adenocarcinoma (HT-29) epithelial cells. Cells were exposed to varying concentrations (25, 50, and 100 µg/mL) of the M. smilacifolium sample for 24 hours post-LPS activation. The anti-inflammatory capacity was monitored by evaluating the inhibition of cyclooxygenase (COX) and lipoxygenase (LOX) enzymatic pathways within cell lysates. The sample demonstrated dose-dependent protective effects, achieving a maximum COX inhibition of 40.291% (IC50= 128.743 µg/mL) and a maximum LOX inhibition of 47.619% (IC50= 103.572 µg/mL) at 100 µg/mL. These findings indicate that M. smilacifolium serves as a viable source of natural dual COX/LOX inhibitors capable of attenuating epithelial inflammatory responses.

Keywords

Myxopyrum smilacifolium, Anti-inflammatory, HT-29 cells

Full Text:

Download Paper PDF

References

1. Walker MC, Gierse JK. In vitro assays for cyclooxygenase activity and inhibitor characterization. Methods Mol Biol. 2010;644:131–144.
2. Axelrod B, Cheesbrough TM, Laakso S. Lipoxygenases in soybean. Meth Enzymol. 1981;71:441–451.
3. Salter M, Duffy C, Garthwaite J, Strijbos PJ. Ex vivo measurement of brain tissue nitrite and nitrate accurately reflects nitric oxide synthase activity in vivo. J Neurochem. 1996;66:1683–1690.
4. Lepoivre M, Chenais B, Yapo A, Lemaire G, Thelander L, Tenu JP, et al. Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells. J Biol Chem. 1990;265:14143–14149.
5. Samu J, Siju EN. In vitro anti-inflammatory activity of Myxopyrum smilacifoliumBlume by HRBC membrane stabilization method. Int J Chem Pharm Res. 2017;9(4):112-115.
6. Peeriga R. Pharmacognostical investigation and preliminary phytochemical screening of leaves of Myxopyrum smilacifolium Pharmacogn J. 2016;8(2):133-138.
7. Sudha S, Marimuthu K, Rajendran R. Phytochemical screening and evaluation of ethanolic extract of Myxopyrum serratulumW. Hill for anti-inflammatory and anti-arthritic activities. J Ethnopharmacol. 2024;312:114-122.
8. Gopalakrishnan V, Ramasamy M, Devadas S. In silico assessment of phytoconstituents in Myxopyrum smilacifoliumBlume against arthritis targeting COX-2. Biomed Pharmacol J. 2024;17(1):215-224.
9. Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62(6):501-509.
10. Meshram GA, Kadam V, Patil S. Natural product-driven dual COX-LOX inhibitors: A review on phytochemicals and bioactive fractions. Phytomedicine. 2023;112:154-168.
11. Singh P, Khan S, Al-Otaibi SM. Dual synergistic inhibition of COX and LOX by potential bioactive compounds from herbs. Sci Rep. 2023;13:35161.
12. Medeiros R, Santos AR, Passos GF. Mechanisms underlying the anti-inflammatory profile of triterpenoids and flavonoids in intestinal epithelial models. Biochem Pharmacol. 2011;82(4):345-356.
13. Kim EK, Lee H, Choi YJ. Anticancer effects in HT-29 cells and anti-inflammatory effects of natural bioactive compounds. Appl Sci. 2023;13(17):9684.
14. Farsi G, Mortazavi M, Zare R. Lovage extracts diminish the expression level of inflammatory genes and COX-2 protein in HT-29 colorectal cells. Gastrointest Med J. 2024;8(2):33-41.
15. Thomas S, Robinson K, Alberts B. Celecoxib and combination therapy profiles in chronic inflammation-associated colorectal cancer. Cell Mol Biol. 2019;65(3):1172-1178.
16. Nair RS, George M, Joseph L. In vivo anti-inflammatory and antipyretic evaluation of Myxopyrum smilacifoliumleaves extract. Asian J Pharm Clin Res. 2015;8(4):104-108.
17. Anitha R, Selvam P. Isolation and total phenolic and flavonoid content estimation in fractions of Myxopyrum smilacifolium(Wall.) Blume. Int J Pharm Pharm Sci. 2022;14(1):107-111.
18. Calder PC. Biological significance of arachidonic acid cascade targets in intestinal mucosal inflammation. Gastroenterology. 2018;154(5):1221-1235.
19. Sharaf EL, Din AM, Salem HA. Lipopolysaccharide-induced inflammatory signaling mechanisms in human intestinal epithelial HT-29 cells. J Immunol. 2015;194(2):789-798.
20. Al-Malki AL, Moselhy SS. Recent advances in dual COX/LOX inhibitor design (2020–2024): Establishing structural parameters for inflammation resolution. Life Sci. 2024;336:120-134.